Article
Oncology
Eileen Rakovitch, Rinku Sutradhar, Sharon Nofech-Mozes, Sumei Gu, Cindy Fong, Wedad Hanna, Lawrence Paszat
Summary: The 21-gene recurrence score can predict breast cancer mortality in individuals with DCIS, and when combined with age (50 years or younger), it can identify individuals who may benefit from radiotherapy.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2021)
Article
Oncology
Sung-Hsin Kuo, Ling-Ming Tseng, Shou-Tung Chen, Yasuaki Sagara, Yuan-Ching Chang, Hsien-Tang Yeh, Yao-Lung Kuo, Chih-Chiang Hung, Tzu-Pin Lu, Yi-Hsuan Lee, Masakazu Toi, Chiun-Sheng Huang
Summary: This study aims to determine whether low-dose tamoxifen is as effective as radiotherapy in preventing breast tumor recurrence in low-risk breast DCIS patients.
Review
Oncology
Amanda L. L. Nash, E. Shelley Hwang
Summary: The management of ductal carcinoma in situ (DCIS) has evolved along with our understanding of its natural history. Early trials showed the benefit of adjuvant therapies for all DCIS patients. However, subsequent studies have categorized patients to determine appropriate less invasive and less intensive treatments. Large trials and analyses have supported the shift away from uniformly intense treatment for DCIS and towards tailored management. This review highlights the landmark studies that form the basis of current DCIS management.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Christopher Li, Meghan R. Flanagan, Mei-Tzu C. Tang, Peggy L. Porter, Kathleen E. Malone
Summary: This study demonstrates that bisphosphonate use is associated with a lower risk of subsequent invasive breast cancer among women with a history of DCIS, suggesting a potential preventative approach for this high-risk population.
Article
Gastroenterology & Hepatology
Ulrike Heger, Claudia Mack, Christine Tjaden, Feng Pan, Thomas Pausch, Ulf Hinz, Christof M. Sommer, Thilo Hackert
Summary: The study investigated the safety, feasibility, and oncologic outcomes of open IRE for unresectable ILR of PDAC. Results showed that in this specific subset of patients, IRE may improve survival, with postoperative complication types and frequencies similar to LAPC.
Article
Gastroenterology & Hepatology
Jae Ri Kim, Hongbeom Kim, Wooil Kwon, Jin-Young Jang, Sun-Whe Kim
Summary: This study on pancreatic ductal adenocarcinoma (PDAC) patients identified different types of recurrence and frequent locations of local recurrence, with preoperative tumor location correlating with the rate of local recurrence.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Si Eun Lee, Ga Ram Kim, Kyunghwa Han, Eun Hwa Kim, Eun-Kyung Kim, Min Jung Kim, Jung HyunYoon, Vivian Youngjean Park, Hee Jung Moon
Summary: A preoperative model using ultrasound and mammography features can accurately identify low nuclear grade DCIS, which helps to avoid surgical treatment for these patients.
Article
Oncology
Mangesh A. Thorat, Pauline M. Levey, J. Louise Jones, Sarah E. Pinder, Nigel J. Bundred, Ian S. Fentiman, Jack Cuzick
Summary: The study found that ER expression is a strong predictor of ipsilateral recurrence risk in ductal carcinoma in situ. Patients with multi-clonal ER expression and patients with uni-clonal ER expression faced similarly higher risks of ipsilateral breast events.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Andrea DeCensi, Harriet Johansson, Thomas Helland, Matteo Puntoni, Debora Macis, Valentina Aristarco, Silvia Caviglia, Tania Buttiron Webber, Irene Maria Briata, Mauro D'Amico, Davide Serrano, Aliana Guerrieri-Gonzaga, Ersilia Bifulco, Steinar Hustad, Havard Soiland, Luca Boni, Bernardo Bonanni, Gunnar Mellgren
Summary: Low-dose tamoxifen can reduce the risk of recurrence in non-invasive breast cancer by half without significant adverse events. Most subjects treated with 5 mg/day have endoxifen levels below 9 nM, and there is no significant association with recurrence, indicating that tamoxifen failure is not related to poor drug metabolism.
Article
Oncology
Melody A. Cobleigh, Stewart J. Anderson, Kalliopi P. Siziopikou, Douglas W. Arthur, Rachel Rabinovitch, Thomas B. Julian, David S. Parda, Samantha A. Seaward, Dennis L. Carter, Janice A. Lyons, Melissa S. Dillmon, Gustav C. Magrinat, Vivek S. Kavadi, Allison M. Zibelli, Lavanya Tiriveedhi, Matthew L. Hill, Marianne K. Melnik, Sushil Beriwal, Eleftherios P. Mamounas, Norman Wolmark
Summary: The B-43 trial aimed to evaluate the efficacy of RT alone vs RT plus T in preventing IBTR in DCIS patients. The addition of T did not achieve the intended 36% reduction in IBTR rate, but did show a modest and statistically nonsignificant 19% reduction. Further exploration of RT plus T in HER2-positive DCIS patients is needed before routine delivery in patients with DCIS resected by lumpectomy.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Pathology
Stuart J. Schnitt
Summary: The article reviews the epidemiology, natural history, and current treatment options for DCIS and discusses ongoing efforts to de-escalate treatment for these patients.
Review
Radiology, Nuclear Medicine & Medical Imaging
Tae-Hyung Kim, Jeong Min Lee, Dong Ho Lee, Ijin Joo, Sae-Jin Park, Jung Hee Yoon
Summary: This study compared the local tumor progression (LTP) of percutaneous no-touch radiofrequency ablation (NtRFA) with conventional radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) <= 5 cm through a systematic review and meta-analysis. The results showed that NtRFA had a lower LTP rate of 6% compared to conventional RFA.
EUROPEAN RADIOLOGY
(2023)
Review
Medicine, General & Internal
Drissa Ouattara, Carole Mathelin, Tolga Ozmen, Massimo Lodi
Summary: This study evaluated the impact of adjuvant radiotherapy (RT) on local recurrence (LR) in women with ductal carcinoma in situ (DCIS) treated by breast-conserving surgery (BCS) according to molecular signature risk stratification. The results showed that, in the high-risk group, BCS + RT significantly reduced the risks of invasive and total breast events (InvBE and TotBE). However, in the low-risk group, RT only had a significant benefit in preventing TotBE, not InvBE. Overall, molecular signatures can help guide the decision of RT in DCIS patients, with high-risk patients benefiting more from RT.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Libo Yang, Mengjia Shen, Yan Qiu, Tingting Tang, Hong Bu
Summary: This study analyzed the clinical features and prognosis of primary ductal carcinoma in situ (DCIS) patients with lumpectomy, based on different molecular subtypes. The results showed diverse characteristics and outcomes among the molecular subtypes, with different effects of radiotherapy on prognosis. Adjusting treatment strategies according to DCIS molecular subtypes is worth considering.
Review
Cell Biology
Ruwangi Udayasiri, Tongtong Luo, Kylie L. Gorringe, Stephen B. Fox
Summary: Ductal carcinoma in situ (DCIS) is a non-invasive breast tumor with the potential to progress to invasive ductal carcinoma (IDC). The current inability to accurately predict the invasive potential of DCIS leads to both over-treatment and under-treatment in patients. Better understanding of the molecular features of DCIS could improve treatment decision-making and avoid unnecessary side-effects. This review summarizes the current knowledge of DCIS and discusses future research directions.
Article
Pathology
Paola Rafaniello-Raviele, Ilaria Betella, Alessandra Rappa, Davide Vacirca, Gianluca Tolva, Aliana Guerrieri-Gonzaga, Lucio Bertario, Massimo Barberis, Bernardo Bonanni, Monica Marabelli
Summary: In this study, the reliability and accuracy of the Idylla MSI assay in EC samples were evaluated and compared with routine methods. The results showed a high concordance between Idylla detection and IHC, suggesting that Idylla MSI assay could be a reliable alternative to conventional methods.
JOURNAL OF CLINICAL PATHOLOGY
(2023)
Article
Oncology
Giovanni Corso, Antonia Girardi, Mariarosaria Calvello, Sara Gandini, Aurora Gaeta, Monica Marabelli, Francesca Magnoni, Paolo Veronesi, Aliana Guerrieri-Gonzaga, Bernardo Bonanni
Summary: This study investigates the impact of different subtypes of pathogenic BRCA variants on the prognosis and survival of breast cancer patients. The findings suggest that the missense/splicing subtypes of BRCA1/2 mutations are associated with a lower risk of breast cancer recurrence.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Review
Biochemistry & Molecular Biology
Tania Buttiron Webber, Irene Maria Briata, Andrea DeCensi, Isabella Cevasco, Laura Paleari
Summary: Taste and smell disorders are common side effects in cancer patients, and identifying the treatments that cause them is important for improving patients' quality of life. This review examined the oncological treatments associated with taste and smell changes and their timing of onset. Fourteen studies were included, showing a high heterogeneity. Drugs such as Docetaxel, paclitaxel, nab-paclitaxel, capecitabine, cyclophosphamide, epirubicin, anthracyclines, and oral 5-FU analogues were found to be the most frequently associated with taste and smell disorders. The review highlights the need for further research, particularly focused on prevention.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Matteo Lazzeroni, Matteo Puntoni, Aliana Guerrieri-Gonzaga, Davide Serrano, Luca Boni, Tania Buttiron Webber, Marianna Fava, Irene M. Briata, Livia Giordano, Maria Digennaro, Laura Cortesi, Fabio Falcini, Patrizia Serra, Franca Avino, Francesco Millo, Katia Cagossi, Elisa Gallerani, Alessia De Simone, Anna Cariello, Giuseppe Aprile, Maria Renne, Bernardo Bonanni, Andrea DeCensi
Summary: This study suggests that low-dose tamoxifen significantly reduces the risk of recurrence in women with intraepithelial neoplasia (IEN) without additional adverse events. Even 7 years after treatment cessation, low-dose tamoxifen still effectively prevents recurrence from noninvasive breast cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Genetics & Heredity
Mariarosaria Calvello, Monica Marabelli, Sara Gandini, Elena Marino, Loris Bernard, Matteo Dal Molin, Giulia Di Cola, Cristina Zanzottera, Giovanni Corso, Nicola Fazio, Lorenzo Gervaso, Uberto Fumagalli Romario, Massimo Barberis, Aliana Guerrieri-Gonzaga, Lucio Bertario, Davide Serrano, Bernardo Bonanni
Summary: Gastric cancer has traditionally been overlooked in hereditary cancer research, but the advent of multigene panel testing has shed light on the involvement of additional genes, particularly those related to homologous recombination repair. Our study identified CDH1 and MSH2 as genes associated with early-onset diffuse and later-onset intestinal gastric cancers, respectively. Multigene panel testing was found to be advantageous in patients with unspecific phenotypes, although it posed challenges in result interpretation.
Article
Oncology
Davide Serrano, Sara Gandini, Parjhitham Thomas, Katherine D. Crew, Nagi B. Kumar, Lana A. Vornik, J. Jack Lee, Paolo Veronesi, Giuseppe Viale, Aliana Guerrieri-Gonzaga, Matteo Lazzeroni, Harriet Johansson, Mauro D'Amico, Flavio Guasone, Stefano Spinaci, Bjorn-Erik Bertelsen, Gunnar Mellgren, Isabelle Bedrosian, Diane Weber, Tawana Castile, Eileen Dimond, Brandy M. Heckman-Stoddard, Eva Szabo, Powel H. Brown, Andrea DeCensi, Bernardo Bonanni
Summary: This study compared different dosing schedules of exemestane, an aromatase inhibitor, in patients with breast cancer. The results showed that a 25mg dose taken three times weekly was as effective as a daily dose in decreasing serum estradiol levels, suggesting that this alternative schedule warrants further investigation.
Article
Biochemistry & Molecular Biology
Davide Serrano, Federica Bellerba, Harriet Johansson, Debora Macis, Valentina Aristarco, Chiara A. Accornero, Aliana Guerrieri-Gonzaga, Cristina M. Trovato, Maria Giulia Zampino, Emanuela Omodeo Sale, Bernardo Bonanni, Sara Gandini, Patrizia Gnagnarella
Summary: Vitamin D deficiency is associated with colorectal cancer (CRC), while adherence to World Cancer Research Fund (WCRF) recommendations significantly reduces the risk of developing CRC. In a randomized trial, CRC patients showed gender and microbiota-specific responses to Vitamin D supplementation. Following WCRF recommendations was associated with lower levels of leptin and IL-6, as well as a lower risk of events. Vitamin D supplementation did not have a significant impact on circulating biomarkers or follow-up events.
Article
Biochemistry & Molecular Biology
Giovanni Corso, Monica Marabelli, Mariarosaria Calvello, Sara Gandini, Matilde Risti, Irene Feroce, Sara Mannucci, Antonia Girardi, Alessandra Margherita De Scalzi, Francesca Magnoni, Elena Marino, Loris Bernard, Paolo Veronesi, Elena Guerini-Rocco, Massimo Barberis, Aliana Guerrieri-Gonzaga, Bernardo Bonanni
Summary: Metaplastic breast cancer (MpBC), a rare and aggressive subtype, has been linked to BRCA1 gene involvement. A retrospective study found that 65% of MpBC patients harbored a pathogenic variant (PV), with the majority in BRCA1. BRCA carriers had a significantly higher risk of developing MpBC compared to other breast cancer patients tested for BRCA genes. The prevalence of MpBCs was significantly different between BRCA1 and BRCA2 carriers. Further studies are needed to elucidate the role of BRCA1 and explore other genes' implication in MpBC predisposition.
EUROPEAN JOURNAL OF HUMAN GENETICS
(2023)
Review
Nutrition & Dietetics
Carla Micaela Cuttica, Irene Maria Briata, Andrea DeCensi
Summary: It is established that obesity is associated with higher cancer incidence. Effective obesity treatment provides new perspectives in managing a modifiable cancer risk factor. This review summarizes the correlations between weight loss in obesity and cancer, exploring the potential of obesity treatment in clinical cancer management. The evidence for the effects of obesity therapy on proliferation, apoptosis, and chemotherapy response is reviewed. Further studies and collaboration among oncologists and obesity treatment experts are needed to fully evaluate the relationship between anti-obesity treatment and cancer.
Article
Nutrition & Dietetics
Debora Macis, Irene Maria Briata, Oriana D'Ecclesiis, Harriet Johansson, Valentina Aristarco, Tania Buttiron Webber, Massimo Oppezzi, Sara Gandini, Bernardo Bonanni, Andrea Decensi
Summary: This study found that the combination treatment of curcumin and anthocyanins did not directly affect circulating biomarkers of inflammation and metabolism, but revealed a complex modulation of inflammatory and metabolic biomarkers of colon carcinogenesis.
Review
Health Care Sciences & Services
Eliza Del Fiol Manna, Davide Serrano, Gaetano Aurilio, Bernardo Bonanni, Matteo Lazzeroni
Summary: Female breast cancer is a common malignancy worldwide. Risk assessment helps identify those at higher risk, and personalized interventions can decrease breast cancer incidence. Chemoprevention has shown benefits in reducing breast cancer incidence in high-risk women, but its effectiveness in BRCA gene carriers is still controversial.